GKOUNTAKOS, ANASTASIOS
 Distribuzione geografica
Continente #
NA - Nord America 430
EU - Europa 369
AS - Asia 166
OC - Oceania 2
AF - Africa 1
SA - Sud America 1
Totale 969
Nazione #
US - Stati Uniti d'America 427
CN - Cina 129
IT - Italia 91
SE - Svezia 58
GB - Regno Unito 56
IE - Irlanda 50
FR - Francia 36
RU - Federazione Russa 32
SG - Singapore 16
DE - Germania 15
FI - Finlandia 14
KR - Corea 8
UA - Ucraina 8
IR - Iran 4
CA - Canada 3
NL - Olanda 3
AU - Australia 2
BG - Bulgaria 2
JP - Giappone 2
AZ - Azerbaigian 1
BY - Bielorussia 1
CL - Cile 1
ES - Italia 1
HK - Hong Kong 1
IL - Israele 1
IN - India 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MA - Marocco 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 969
Città #
Chandler 114
Southend 52
Dublin 48
Beijing 42
Verona 34
Jacksonville 27
New York 22
Ashburn 16
Kent 16
Ann Arbor 15
Wilmington 15
Lawrence 14
Princeton 14
Jinan 12
Woodbridge 11
Singapore 10
Helsinki 8
Nanjing 8
Seoul 8
Milan 7
Seattle 7
Tianjin 6
Hebei 5
Redmond 5
Redwood City 5
Sindelfingen 5
Cagliari 4
Falls Church 4
Jiaxing 4
Lappeenranta 4
Shenyang 4
Zhengzhou 4
Arzignano 3
Boardman 3
Brescia 3
Guangzhou 3
Hangzhou 3
Orlando 3
Rome 3
Boydton 2
Cambridge 2
Chions 2
Dongguan 2
Nanchang 2
Ningbo 2
Pieve di Soligo 2
Riva 2
Sossano 2
Taizhou 2
Tokyo 2
Toronto 2
Amsterdam 1
Ardabil 1
Augusta 1
Baku 1
Burgas 1
Changsha 1
Charlotte 1
Chicago 1
Cologne 1
Dearborn 1
Edinburgh 1
Fremont 1
Fuzhou 1
Haikou 1
Hong Kong 1
Houston 1
Illasi 1
Isola della Scala 1
Karlsruhe 1
Kashan 1
Lanzhou 1
Laredo 1
Lombard 1
London 1
Los Angeles 1
Madrid 1
Manila 1
Martano 1
Melbourne 1
Messina 1
Miami 1
Minsk 1
Montréal 1
Moscow 1
Mumbai 1
Negrar 1
Newark 1
Norwalk 1
Pozza di Fassa 1
Riga 1
San Francisco 1
San Mateo 1
Sofia 1
Taiyuan 1
Tashkent 1
Tel Aviv 1
Tolentino 1
Vientiane 1
Washington 1
Totale 644
Nome #
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 82
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 70
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 70
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 64
Assessing the potential role of Rictor expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer 61
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 60
Muscle derangement and alteration of the nutritional machinery in NSCLC 60
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 58
Physical activity and exercise in lung cancer care: will promises be fulfilled? 57
Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients 52
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma 51
Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology 49
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 46
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 40
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 34
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 28
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance 25
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 23
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 23
An Insight on Functioning Pancreatic Neuroendocrine Neoplasms 22
An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide 19
Comprehensive characterization of intraductal oncocytic papillary neoplasm (IOPN) of the pancreas: a systematic and critical review 10
Fusion genes in pancreatic tumors 9
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives 7
Totale 1.020
Categoria #
all - tutte 4.465
article - articoli 3.770
book - libri 0
conference - conferenze 510
curatela - curatele 0
other - altro 185
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.930


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202081 0 1 1 3 10 4 6 11 15 9 7 14
2020/2021107 9 11 2 22 14 13 3 3 3 3 13 11
2021/2022136 7 40 4 12 6 2 2 16 10 1 8 28
2022/2023329 16 37 24 52 30 60 7 24 60 1 8 10
2023/2024262 10 23 29 19 24 35 22 27 5 16 44 8
2024/202544 28 16 0 0 0 0 0 0 0 0 0 0
Totale 1.020